Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xia He

Showing results (801-810 of 811) with videos related to

Pageof 82
Sort By:
Emerging Microbes & Infections|November 18, 2022
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, ChinaHongqin Xu, Hongyan Li, Hailong You, et al.
Therapeutic Advances in Medical Oncology|October 14, 2024
Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphomaFei Luo, Qiu-Zi Zhong, Xin Liu, et al.
Neuro-Oncology Advances|May 29, 2026
An ambispective, observational real-world study of tumor-treating fields for treatment of Chinese patients with newly diagnosed or recurrent/progressive glioblastomaGuanzhang Li, Xiaoguang Qiu, Wei Zhang, et al.
Annals of Hematology|June 12, 2023
Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG studyJia-Ying Li, Xiao-Rong Hou, Si-Ye Chen, et al.
Leukemia|March 11, 2020
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-makingSi-Ye Chen, Yong Yang, Shu-Nan Qi, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
The Lancet Regional Health. Western Pacific|March 7, 2023
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 studyYuankai Shi, Xintian Qin, Xingchen Peng, et al.
Zhonghua Fu Chan Ke Za Zhi|March 3, 2010
[Epidemiological study of high risk human papillomavirus infection in 25 to 54 years old married women in Beijing.]Ming-Hui Wu, Song-Wen Zhang, Wei-Yuan Zhang, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
Pageof 82

Showing results (801-810 of 811) with videos related to

Sort By:
Pageof 82
Emerging Microbes & Infections|November 18, 2022
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, ChinaHongqin Xu, Hongyan Li, Hailong You, et al.
Therapeutic Advances in Medical Oncology|October 14, 2024
Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphomaFei Luo, Qiu-Zi Zhong, Xin Liu, et al.
Neuro-Oncology Advances|May 29, 2026
An ambispective, observational real-world study of tumor-treating fields for treatment of Chinese patients with newly diagnosed or recurrent/progressive glioblastomaGuanzhang Li, Xiaoguang Qiu, Wei Zhang, et al.
Annals of Hematology|June 12, 2023
Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG studyJia-Ying Li, Xiao-Rong Hou, Si-Ye Chen, et al.
Leukemia|March 11, 2020
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-makingSi-Ye Chen, Yong Yang, Shu-Nan Qi, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
The Lancet Regional Health. Western Pacific|March 7, 2023
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 studyYuankai Shi, Xintian Qin, Xingchen Peng, et al.
Zhonghua Fu Chan Ke Za Zhi|March 3, 2010
[Epidemiological study of high risk human papillomavirus infection in 25 to 54 years old married women in Beijing.]Ming-Hui Wu, Song-Wen Zhang, Wei-Yuan Zhang, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
Pageof 82